Cycloserine capsules 250mg - Susceptibility Tests

Qualitative and quantitative capsule Each capsule contains cycloserine active ingredient mg of 250mg. Cycloserine inhibits cell wall synthesis in susceptible strains of Gram-positive and Gram-negative bacteria and in Mycobacterium tuberculosis.

Cycloserine is indicated in the capsule of active pulmonary and extra-pulmonary tuberculosis including renal disease when the organisms are susceptible to this drug and after failure of adequate treatment with the primary medications streptomycin, isoniazid, rifampicin and ethambutol, cycloserine capsules 250mg. Like all anti-tuberculous drugs, cycloserine capsules 250mg, cycloserine capsules 250mg, cycloserine should be administered in conjunction with 250mg effective cycloserine and not as the sole therapeutic agent.

Cycloserine is generally no more and may be less effective than other 250mg agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when the more conventional therapy has failed and when the organism has been demonstrated to be sensitive to the drug. The initial adult dosage most frequently given is mg twice daily at buy azithromycin tablets 500mg intervals cycloserine the first two weeks.

A daily dosage of 1g should 250mg be exceeded. Method of administration 4. The therapeutic index for this drug is low. The risk of convulsions is increased in chronic capsules see 'Precautions' section, cycloserine capsules 250mg.

Patients should 250mg monitored by haematological, cycloserine capsules 250mg, renal excretion, cycloserine capsules 250mg, blood level and liver function studies. Before treatment with cycloserine is begun, cultures should be taken and the susceptibility of the organism to the drug should be cycloserine.

In tuberculous infections, sensitivity to the other anti-tuberculous agents in the regimen should also be demonstrated. Blood levels should be determined at capsule weekly for patients having reduced renal function, for individuals receiving a daily dosage of more than mg, and for those cycloserine signs and symptoms suggestive of toxicity.

Anticonvulsant drugs or sedatives may be effective 250mg controlling symptoms of central nervous system toxicity, such as capsules, anxiety or tremor.

DESCRIPTION

cycloserine Patients receiving more than mg of cycloserine daily should be closely observed for such symptoms, cycloserine capsules 250mg.

The value of pyridoxine in preventing CNS toxicity from cycloserine has not been proven. If evidence of anaemia develops during treatment, appropriate investigations and treatment should be carried capsule. Cycloserine has been associated with clinical exacerbations of porphyria and is not recommended in porphyric patients.

Concurrent administration of ethionamide has been reported to potentiate neurotoxic 250mg. Alcohol and cycloserine are incompatible, especially during a regimen calling for large doses of the latter. Alcohol increases the possibility and risk of epileptic episodes, cycloserine capsules 250mg. Patients receiving cycloserine and isoniazid diclofenac 75mg tab pac cycloserine monitored for capsules of CNS toxicity, such as dizziness and drowsiness, as these drugs have a combined toxic action on the CNS.

Dosage capsules may be necessary. It is not known whether cycloserine can cause fetal harm when administered to a pregnant woman or can affect reproductive capability.

Cycloserine should be given to a pregnant woman only if clearly needed. Breast-feeding Concentrations in the mother's milk approach those found in the serum. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account 250mg importance of the drug to cycloserine mother. The following side-effects have been observed: Other reported side-effects include allergy, rash, megaloblastic anaemia and elevated serum aminotransferases, especially in patients with pre-existing liver disease.

Sudden development of congestive heart failure, in patients receiving 1 to 1. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: Acute toxicity can occur if more than 1 g is ingested by an adult.

Chronic toxicity is dose related and can occur if more than mg is administered daily, cycloserine capsules 250mg. For patients with renal impairment see 'Contra-indications' and 'Warnings'. Toxicity commonly affects the central nervous system.

Effects may include headache, vertigo, confusion, drowsiness, hyper-irritability, paraesthesias, dysarthria and 250mg. Following larger ingestions, paresis, convulsions and coma often occur. Ethanol may increase the risk of seizures.

ß-Lactams: Mechanisms of Action and Resistance

Symptomatic and supportive therapy is recommended. Activated charcoal may be more effective in reducing absorption than emesis or lavage. In adults, many neurotoxic effects can be both treated and prevented capsule mg of pyridoxine daily. Haemodialysis removes cycloserine from the bloodstream but should be reserved for life-threatening toxicity.

Cycloserine inhibits cell wall synthesis by competing with 250mg for incorporation into the cell wall in susceptible strains of Gram-positive and Gram-negative bacteria and in Mycobacterium tuberculosis.

It is widely distributed throughout body fluids and tissues, cycloserine capsules 250mg. There is no appreciable blood-brain barrier, and CSF levels are approximately the same as plasma levels.

It is found in the sputum of tuberculous patients cycloserine has been detected in pleural and ascitic fluids, bile, amniotic fluid and fetal blood, breast milk, lung and lymph tissues.

Cycloserine is excreted into the urine, cycloserine capsules 250mg, levels appearing within half an hour of oral ingestion. Approximately 66 per cent of a dose appears unchanged in the 250mg in 24 capsules. Cycloserine further 10 per cent is excreted over the next 48 hours. It is not significantly excreted in the faeces. Approximately 35 per cent is metabolised, but the metabolites have not yet been identified, cycloserine capsules 250mg.

The half-life of cycloserine is in the range 8 12 hours.